ClinicaliQ Trial Snapshot
- A Study of Eptinezumab in Pediatric Participants With Episodic Migraine — Recruiting • Phase III • NCT05897320.
- Eptinezumab reduced migraine days in children with episodic migraine.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants. Conditions: Episodic Migraine Interventions: Eptinezumab, Placebo Lead Sponsor: H. Lundbeck A/S Planned Enrollment: 315 participants